Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Efficacy and Safety of RNK08954 in Subjects With KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07303465 is registered in ClinicalTrials.gov with Ranok Therapeutics (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT07303465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07303465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Efficacy and Safety of RNK08954 in Subjects With KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
October 14, 2025
Completion date
November 30, 2026
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kras g12d mutations, pancreatic ductal adenocarcinoma (pdac)